{"id":54285,"date":"2026-01-15T22:46:32","date_gmt":"2026-01-15T14:46:32","guid":{"rendered":"https:\/\/flcube.com\/?p=54285"},"modified":"2026-04-23T21:53:44","modified_gmt":"2026-04-23T13:53:44","slug":"ipsens-ipn60340-wins-fda-breakthrough-therapy-designation-for-first-line-aml-in-combination","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54285","title":{"rendered":"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination"},"content":{"rendered":"\n<p><strong>Ipsen S.A.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/IPN:EPA\">EPA:\u202fIPN<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/IPSEY:OTCMKTS\">OTCMKTS:\u202fIPSEY<\/a>) announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> for <strong>IPN60340<\/strong> in combination with <strong>venetoclax and azacitidine (Ven\u2011Aza)<\/strong> for <strong>first\u2011line unfit acute myeloid leukemia (AML)<\/strong>, an aggressive blood cancer affecting older adults.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>IPN60340 (first\u2011in\u2011class monoclonal antibody)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. FDA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First\u2011line unfit AML in combination with Ven\u2011Aza<\/td><\/tr><tr><td><strong>Mechanism of Action<\/strong><\/td><td>Targets BTN3A, a key immune\u2011regulatory molecule broadly expressed across cancer<\/td><\/tr><tr><td><strong>Previous Designations<\/strong><\/td><td>Orphan Drug Designation (FDA &amp; EMA, July\u202f2025)<\/td><\/tr><tr><td><strong>Clinical Data<\/strong><\/td><td>Phase\u202f1\/2 EVICTION trial showed improved outcomes and favorable tolerability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-1-2-eviction-trial\">Clinical Evidence \u2013 Phase\u202f1\/2 EVICTION Trial<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population:<\/strong> Patients with first\u2011line unfit AML<\/li>\n\n\n\n<li><strong>Regimen:<\/strong> IPN60340 + venetoclax + azacitidine (Ven\u2011Aza)<\/li>\n\n\n\n<li><strong>Key Findings:<\/strong><\/li>\n\n\n\n<li><strong>Well\u2011tolerated safety profile<\/strong><\/li>\n\n\n\n<li><strong>Improved clinical outcomes<\/strong> vs. historical Ven\u2011Aza controls<\/li>\n\n\n\n<li><strong>Durable responses<\/strong> observed in heavily pretreated elderly population<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Ipsen plans to discuss <strong>Phase\u202f2\/3 development plans<\/strong> with FDA in <strong>H1\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>US<\/th><th>EU<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>New AML Cases (2026E)<\/strong><\/td><td>21,000<\/td><td>18,000<\/td><td>75,000<\/td><\/tr><tr><td><strong>Unfit for Intensive Chemo<\/strong><\/td><td>12,600 (60\u202f%)<\/td><td>10,800 (60\u202f%)<\/td><td>45,000 (60\u202f%)<\/td><\/tr><tr><td><strong>Ven\u2011Aza Standard of Care<\/strong><\/td><td>70\u202f% penetration<\/td><td>65\u202f% penetration<\/td><td>68\u202f% penetration<\/td><\/tr><tr><td><strong>IPN60340 Addressable Market<\/strong><\/td><td>8,800<\/td><td>7,000<\/td><td>30,600<\/td><\/tr><tr><td><strong>Annual Cost (Ven\u2011Aza)<\/strong><\/td><td>$180,000<\/td><td>\u20ac150,000<\/td><td>\u2013<\/td><\/tr><tr><td><strong>IPN60340 Peak Market Share<\/strong><\/td><td>0\u202f%<\/td><td>0\u202f%<\/td><td>18\u202f%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>$285\u202fmillion<\/td><td>$189\u202fmillion<\/td><td>$824\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ven\u2011Aza<\/strong> (AbbVie\/Roche) \u2013 Current standard of care for unfit AML<\/li>\n\n\n\n<li><strong>Glasdegib + LDAC<\/strong> (Pfizer) \u2013 Alternative for unfit patients<\/li>\n\n\n\n<li><strong>IPN60340<\/strong> \u2013 <strong>First BTN3A\u2011targeted therapy<\/strong> with potential to <strong>enhance Ven\u2011Aza efficacy<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Advantage:<\/strong> IPN60340 is the <strong>only BTN3A\u2011targeted antibody<\/strong> in clinical development for AML, offering a novel immune\u2011modulating mechanism<\/li>\n\n\n\n<li><strong>Combination Strategy:<\/strong> BTD validates the <strong>IPN60340 + Ven\u2011Aza<\/strong> regimen, positioning it as a <strong>potential new standard<\/strong> for unfit AML<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> BTD enables <strong>accelerated FDA review<\/strong>, priority meetings, and potential <strong>rolling submission<\/strong><\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Ipsen plans <strong>EMA submission<\/strong> in <strong>H2\u202f2026<\/strong> following FDA BTD<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and commercial projections for IPN60340. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[34,880,519,881],"class_list":["post-54285","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-breakthrough-therapy","tag-epa-ipn","tag-ipsen-s-a","tag-otcmkts-ipsey"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven\u2011Aza) for first\u2011line unfit acute myeloid leukemia (AML), an aggressive blood cancer affecting older adults.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54285\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination\" \/>\n<meta property=\"og:description\" content=\"Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven\u2011Aza) for first\u2011line unfit acute myeloid leukemia (AML), an aggressive blood cancer affecting older adults.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54285\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T14:46:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T13:53:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54285#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54285\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination\",\"datePublished\":\"2026-01-15T14:46:32+00:00\",\"dateModified\":\"2026-04-23T13:53:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54285\"},\"wordCount\":370,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Breakthrough therapy\",\"EPA: IPN\",\"Ipsen S.A.\",\"OTCMKTS: IPSEY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54285#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54285\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54285\",\"name\":\"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-15T14:46:32+00:00\",\"dateModified\":\"2026-04-23T13:53:44+00:00\",\"description\":\"Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven\u2011Aza) for first\u2011line unfit acute myeloid leukemia (AML), an aggressive blood cancer affecting older adults.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54285#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54285\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54285#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination - Insight, China&#039;s Pharmaceutical Industry","description":"Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven\u2011Aza) for first\u2011line unfit acute myeloid leukemia (AML), an aggressive blood cancer affecting older adults.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54285","og_locale":"en_US","og_type":"article","og_title":"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination","og_description":"Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven\u2011Aza) for first\u2011line unfit acute myeloid leukemia (AML), an aggressive blood cancer affecting older adults.","og_url":"https:\/\/flcube.com\/?p=54285","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-15T14:46:32+00:00","article_modified_time":"2026-04-23T13:53:44+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54285#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54285"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination","datePublished":"2026-01-15T14:46:32+00:00","dateModified":"2026-04-23T13:53:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54285"},"wordCount":370,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Breakthrough therapy","EPA: IPN","Ipsen S.A.","OTCMKTS: IPSEY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54285#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54285","url":"https:\/\/flcube.com\/?p=54285","name":"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-15T14:46:32+00:00","dateModified":"2026-04-23T13:53:44+00:00","description":"Ipsen S.A. (EPA:\u202fIPN, OTCMKTS:\u202fIPSEY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven\u2011Aza) for first\u2011line unfit acute myeloid leukemia (AML), an aggressive blood cancer affecting older adults.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54285#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54285"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54285#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ipsen\u2019s IPN60340 Wins FDA Breakthrough Therapy Designation for First\u2011Line AML in Combination"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54285"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54285\/revisions"}],"predecessor-version":[{"id":54286,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54285\/revisions\/54286"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}